S
Shanghai Allink Biotherapeutics
A clinical-stage biotechnology company pioneering next-generation bispecific antibody and antibody-drug conjugate (ADC) therapeutics
About Shanghai Allink Biotherapeutics
Shanghai Allink Biotherapeutics, established in 2023 and based in Shanghai's Zhangjiang Hi-Tech Park, is a clinical-stage biotechnology firm focused on developing treatments for oncology and immunology. The company specializes in creating bispecific antibodies and antibody-drug conjugates (ADCs). Its business model centers on the research, development, and eventual commercialization of these novel therapeutics. Allink Biotherapeutics leverages its proprietary technology platforms to create next-generation treatments.
The company was founded by Dr. Hui Feng, who serves as CEO. Dr. Feng earned his Ph.D. in Molecular Pharmacology from Albert Einstein College of Medicine and has nearly two decades of experience in the biopharmaceutical industry. His background includes roles at Medimmune (an AstraZeneca subsidiary) and TopAlliance Biosciences. He notably led the development of Toripalimab, China's first PD-1 monoclonal antibody to receive overseas approval. The co-founders include Kehua Fan (COO), who has extensive experience in clinical development and external collaborations, and Dr. Li Li (Head of Research), who holds a Ph.D. from the Shanghai Institute of Materia Medica.
Allink Biotherapeutics' core focus is its pipeline of First-in-Class (FIC) and Best-in-Class (BIC) therapeutics. The company utilizes a proprietary bispecific antibody platform and a novel conjugation technology to produce bispecific ADCs (BsADCs). These are engineered for optimized drug-to-antibody ratios, improved hydrophilicity, and greater stability. The company's pipeline includes more than 10 candidates, with two lead assets, ALK201 and ALK202, having advanced to Phase I clinical trials in the United States, China, and Australia. These trials are assessing the safety, tolerability, and preliminary anti-tumor activity in patients with advanced solid tumors. In November 2024, the company secured $42 million in a Series A financing round led by Lanchi Ventures, with participation from investors such as Legend Capital, Yuanbio Venture Capital, and existing shareholders Gaorong Ventures and Med-Fine Capital. These funds are designated for advancing the clinical development of its lead candidates, enriching its pipeline, and expanding its global operations.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Dec 2025 | $47M | $188M | Lapam Capital · 5Y Capital · Runzhang Venture Capital · Legend Capital | ↗ |
| SERIES AOther financing | Nov 2024 | $42M | $168M | Gaorong Capital · Yuansheng BioVenture · Xiamen C&D · Lanchi Ventures | ↗ |
Growth signals
Latest recorded traffic for Shanghai Allink Biotherapeutics is 1.4K monthly website visits, up 197.9% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shanghai Allink Biotherapeutics in its local ecosystem
The Shanghai Allink Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Lanchi Ventures
Gaorong Capital
Yuansheng BioVenture
Xiamen C&D
Legend Capital
Med-Fine Capital
Lapam Capital
5Y Capital- RCRunzhang Venture Capital
- YCYuanBio Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Allink Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Allink Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









